INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 422m ago
HOUSE PTR22m ago
SEC 13F22m ago
ROBINHOOD CHAIN22m ago
Public company

SLNOSOLENO THERAPEUTICS INC

CIK 0001484565

EDGAR filingsOpen in network
Disclosed transactions28
Buys / sells0 / 6
Max Insider Score33
Connections6with evidence

SLNO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Disposition to issuer
D—
13.8K sh
May 18, 2026May 18, 2026
traded May 18, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Hirano Patricia CSEE REMARKS · Jan 23, 2026
  • ← Insider ofevidence
    Manning MeredithChief Commercial Officer · Jan 23, 2026
  • ← Insider ofevidence
    Huang Michael F.Sr. VP of Clinical Development · Dec 17, 2025
9
JM
Joshi ManherChief Development Officer
SLNOSOLENO THERAPEUTICS INC
Disposition to issuer
D
—
20.2K sh
May 18, 2026
May 18, 2026
traded May 18, 2026
+0d
SEC FORM 4

Evidence

5
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Disposition to issuer
D—
39.8K sh
May 18, 2026May 18, 2026
traded May 18, 2026
+0dSEC FORM 4

Evidence

9
JM
Joshi ManherChief Development Officer
SLNOSOLENO THERAPEUTICS INC
Disposition to issuer
D—
4,700 sh
May 18, 2026May 18, 2026
traded May 18, 2026
+0dSEC FORM 4

Evidence

9
JM
Joshi ManherChief Development Officer
SLNOSOLENO THERAPEUTICS INC
Disposition to issuer
D—
72.3K sh
May 18, 2026May 18, 2026
traded May 18, 2026
+0dSEC FORM 4

Evidence

5
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Disposition to issuer
D—
11.9K sh
May 18, 2026May 18, 2026
traded May 18, 2026
+0dSEC FORM 4

Evidence

5
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Disposition to issuer
D—
110.0K sh
May 18, 2026May 18, 2026
traded May 18, 2026
+0dSEC FORM 4

Evidence

29
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Open-market sale
SELL$57K
1,838 sh
Mar 27, 2026Mar 31, 2026
traded Mar 27, 2026
+4dSEC FORM 4

Evidence

26
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Open-market sale
SELL$15K
488 sh
Mar 27, 2026Mar 31, 2026
traded Mar 27, 2026
+4dSEC FORM 4

Evidence

33
MM
Manning MeredithChief Commercial Officer
SLNOSOLENO THERAPEUTICS INC
Open-market sale
SELL$146K
4,864 sh
Mar 27, 2026Mar 31, 2026
traded Mar 27, 2026
+4dSEC FORM 4

Evidence

29
MM
Manning MeredithChief Commercial Officer
SLNOSOLENO THERAPEUTICS INC
Open-market sale
SELL$65K
2,100 sh
Mar 27, 2026Mar 31, 2026
traded Mar 27, 2026
+4dSEC FORM 4

Evidence

26
MM
Manning MeredithChief Commercial Officer
SLNOSOLENO THERAPEUTICS INC
Open-market sale
SELL$18K
558 sh
Mar 27, 2026Mar 31, 2026
traded Mar 27, 2026
+4dSEC FORM 4

Evidence

33
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Open-market sale
SELL$128K
4,256 sh
Mar 27, 2026Mar 31, 2026
traded Mar 27, 2026
+4dSEC FORM 4

Evidence

17
NK
Norrett KevinChief Business Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
3,500 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

21
HC
Hirano Patricia CSEE REMARKS
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
10.4K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

9
HC
Hirano Patricia CSEE REMARKS
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
11.9K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

21
MM
Manning MeredithChief Commercial Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
28.6K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

9
MM
Manning MeredithChief Commercial Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
32.8K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

9
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
11.9K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

17
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
10.4K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

17
JM
Joshi ManherChief Development Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
4,100 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

9
JM
Joshi ManherChief Development Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
4,700 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

9
NK
Norrett KevinChief Business Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
4,000 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

9
HF
Huang Michael F.Sr. VP of Clinical Development
SLNOSOLENO THERAPEUTICS INC
Tax withholding
F$41K
812 sh
Dec 15, 2025Dec 17, 2025
traded Dec 15, 2025
+2dSEC FORM 4

Evidence

9
NK
Norrett KevinChief Business Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
14.3K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

9
NK
Norrett KevinChief Business Officer
SLNOSOLENO THERAPEUTICS INC
Option exercise
M—
64.3K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

9
JM
Joshi ManherChief Development Officer
SLNOSOLENO THERAPEUTICS INC
Option exercise
M—
72.3K sh
Nov 10, 2025Nov 12, 2025
traded Nov 10, 2025
+2dSEC FORM 4

Evidence

9
JM
Joshi ManherChief Development Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
16.1K sh
Nov 10, 2025Nov 12, 2025
traded Nov 10, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Norrett KevinChief Business Officer · Nov 19, 2025
  • ← Insider ofevidence
    Joshi ManherChief Development Officer · Nov 12, 2025
    • Source error

    Price history for SLNO is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.